[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613482":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":134,"collaborators":12,"id":136,"slug":137,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":12,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":12,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":39,"whyStopped":12,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Efferon JSC","INDUSTRY",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Baseline therapy+ HF\u002FHDF","NO_INTERVENTION","Basic therapy - which is the routine practice of an institution for the treatment of patients with uninfected acute pancreatitis in combination with hemofiltration (HF) or hemodiafiltration (HDF) procedures.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Baseline therapy + HF\u002FHDF + Efferon LPS","EXPERIMENTAL","Patients will receive basic therapy (routine practice of an institution for the treatment of patients with uninfected acute pancreatitis), hemofiltration or hemodiafiltration procedures in combination with hemoadsorption therapy (Efferon LPS).",[18],"Device: Efferon LPS",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","Efferon LPS","Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.\n\nEfferon LPS will be administered in combination with either hemofiltration (HF) or hemodiafiltration (HDF). The choice between HF and HDF will be made by the investigator, based on the individual clinical situation.The therapy will be initiated within the first 24 hours after ICU admission and within 8 hours after patient enrollment.",[14],[26],{"name":27,"affiliation":28,"role":29},"Vladimir Kiselev, PhD, MD","N. V. Sklifosovsky Moscow Research Institute of Emergency","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},"Alexandr Shelehov-Kravchenko, PhD, MD","CONTACT","+79636564765","alexandr.shelehov@gmail.com",[37,54,67,80,90,99,108,121],{"facility":38,"status":39,"city":40,"state":12,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan","RECRUITING","Kazan'","420064","Russia","RU",{"type":45,"coordinates":46},"Point",[47,48],49.12214,55.78874,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":12,"phoneExt":12,"email":53},"Ruslan Zefirov, PhD, MD","ruslan.zefirov@tatar.ru",{"facility":55,"status":39,"city":56,"state":12,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"State Clinical Hospital \"Regional Clinical Hospital No 2\" of the Ministry of Healthcare of Krasnodar Territory","Krasnodar","350012",{"type":45,"coordinates":59},[60,61],38.98178,45.04534,{"lat":61,"lon":60},[64],{"name":65,"role":33,"phone":12,"phoneExt":12,"email":66},"Sergey Sinkov, PhD, MD","ssinkov@yandex.ru",{"facility":68,"status":39,"city":69,"state":12,"zip":70,"country":42,"countryCode":43,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"V.P. Demikhov City Clinical Hospital No. 68","Moscow","115280",{"type":45,"coordinates":72},[73,74],37.61781,55.75204,{"lat":74,"lon":73},[77],{"name":78,"role":33,"phone":12,"phoneExt":12,"email":79},"Makariy Mendibaev, PhD, MD","makariy.mendibaev@yandex.ru",{"facility":81,"status":39,"city":69,"state":12,"zip":82,"country":42,"countryCode":43,"cosmosGeoPoint":83,"geoPoint":85,"contacts":86},"S.S. Yudin City Clinical Hospital","115446",{"type":45,"coordinates":84},[73,74],{"lat":74,"lon":73},[87],{"name":88,"role":33,"phone":12,"phoneExt":12,"email":89},"Nikolai Krotenko, PhD, MD","npkrotenko@gmail.com",{"facility":91,"status":39,"city":69,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"N.I. Pirogov City Clinical Hospital No. 1",{"type":45,"coordinates":93},[73,74],{"lat":74,"lon":73},[96],{"name":97,"role":33,"phone":12,"phoneExt":12,"email":98},"Marat Magomedov, PhD, MD","mma16@bk.ru",{"facility":100,"status":39,"city":69,"state":12,"zip":12,"country":42,"countryCode":43,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},"N.V. Sklifosovsky Research Institute for Emergency Medicine",{"type":45,"coordinates":102},[73,74],{"lat":74,"lon":73},[105],{"name":106,"role":33,"phone":12,"phoneExt":12,"email":107},"Sergey Rey, PhD, MD","fanwal@mail.ru",{"facility":109,"status":39,"city":110,"state":12,"zip":111,"country":42,"countryCode":43,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Perm regional clinical hospital","Perm","614045",{"type":45,"coordinates":113},[114,115],56.25017,58.01046,{"lat":115,"lon":114},[118],{"name":119,"role":33,"phone":12,"phoneExt":12,"email":120},"Alexey Vereshchagin, PhD, MD","veralex.80@mail.ru",{"facility":122,"status":39,"city":123,"state":12,"zip":124,"country":42,"countryCode":43,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"North-Western district scientific and clinical center named after L. G. Sokolov Federal Medical and Biological Agency","Saint Petersburg","194291",{"type":45,"coordinates":126},[127,128],30.31413,59.93863,{"lat":128,"lon":127},[131],{"name":132,"role":33,"phone":12,"phoneExt":12,"email":133},"Ionas Simutis, PhD, MD","simutis@mail.ru",{"type":135,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100613482","efferon-lps-hemoadsorption-in-patients-with-acute-pancreatitis-100613482",false,"NCT07267169","Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Acute Pancreatitis","Inclusion Criteria:\n\n* ≤ 5 days from the onset of acute pancreatitis\n* Acute pancreatitis of moderate or severe according to the Atlanta classification (2012)\n* Acute pancreatitis confirmed by tomography. Modified CTSI Pancreatitis Severity Index Score ≥ 4 points\n* APACHE II \\> 8\n* ≥ 2 points on the Sequential Organ Failure Assessment (SOFA) scale and\u002For ≥ 2 criteria of Systemic Inflammatory Response Syndrome (SIRS):\n* Body temperature ≥ 38 °C or ≤ 36 °C\n* Heart rate ≥ 90\u002Fmin\n* Respiratory rate ≥ 20\u002Fmin or hyperventilation with PaCO₂ ≤ 32 mmHg\n* Leukocytosis (≥ 12,000\u002Fμl) or leukopenia (≤ 4,000\u002Fμl) or left shift of leukocyte formula\n\nExclusion Criteria:\n\n* SOFA score \\> 12 points\n* Presence of an uncontrolled surgical infection focus\n* Development of septic complications - signs of infection\n* Acute pancreatitis as an exacerbation of chronic pancreatitis\n* Blood triglyceride level \\> 1000 mg\u002FdL (11.2 mmol\u002FL)\n* Liver cirrhosis (\\> 6 points by Child-Pugh classification)\n* Unresolved biliary hypertension syndrome\n* BMI ≥ 40\n* Dementia\n* Chronic kidney disease stage 4-5\n* Acute pulmonary embolism confirmed by CT\n* Acute myocardial infarction within the last 4 weeks\n* Acute cerebrovascular accident\n* Severe congestive heart failure\n* Uncontrolled bleeding (acute blood loss within the last 24 hours)","ALL","18 Years","75 Years",{"count":147,"type":148},150,"ESTIMATED","INTERVENTIONAL",[151],"NA","The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) \u002F hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction (measured by SOFA score) in patients with acute pancreatitis.\n\nParticipants will be assigned to two groups for comparison: a control group receiving baseline therapy with HF\u002FHDF, and a treatment group receiving baseline therapy in combination with HF\u002FHDF and Efferon® LPS hemoadsorption.The therapy will be initiated within the first 24 hours after ICU admission and within 8 hours after patient enrollment.",[154],"Pancreatitis, Acute",[156,157],"acute pancreatitis","hemoperfusion","2026-04-06",{"date":160,"type":161},"2026-04-07","ACTUAL",{"date":163,"type":161},"2026-03-30",{"date":165,"type":148},"2028-03-31",{"name":5,"class":6},8]